NEW YORK (

TheStreet

) -- Good Sunday afternoon and welcome to another edition of Weekend Reading. First a look back at the week that just finished, then a look forward at the week ahead, and then a summary of articles and research papers worth reading.

It was a decent week for the major U.S. markets, but gains were more muted than they have been in previous weeks. The

S&P 500

gained 0.5%, the

Dow

was up 0.7% and the

Nasdaq

ended the week up 0.3%.

Blame bank troubles, worries about trade and currencies (China's and the U.S.'s in particular), as well as indifferent earnings. On the other hand, it was a solid week for U.S. IPOs, with six averaging gains of 31%.

Looking ahead to next week, it will be all earnings, all the time, albeit with a continuing backdrop of trade and currencies. Third-quarter earnings season will be solid, with few surprises, so most of the attention will be on guidance. There will be continuing fallout from

this weekend's G20 meeting

, which seems to have produced a group hug but not much else in terms of incentives for countries to play nicely given current trade tensions.

> > Bull or Bear? Vote in Our Poll

Turning to economic indicators, we will see reports in the coming week on existing-home sales, durable goods orders and U.S. third-quarter GDP.

As for earnings, the week will bring reports from

Amgen

(AMGN) - Get Report

,

Texas Instruments

(TXN) - Get Report

,

Ford

(F) - Get Report

,

CB Richard Ellis

(CBG)

,

Waste Management

(WM) - Get Report

, and

Chevron

(CVX) - Get Report

, among a host of others.

Lastly, here are some articles and papers worth reading:

At the time of publication, Kedrosky had no positions in stocks mentioned, although holdings can change at any time.

--Written by Paul Kedrosky in La Jolla, Calif.

>To contact the staff member responsible for this article, click here:

Ross Snel

.

>To follow the writer on Twitter, go to

http://twitter.com/pkedrosky

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Dr. Paul Kedrosky is a former highly ranked sell-side technology equity analyst, and he currently runs a technology finance institute at the University of California, San Diego. He is also a venture partner with Ventures West, an institutional venture capital firm with more than $400 million under management. He maintains a widely read blog called

Infectious Greed

.

Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. While Kedrosky cannot provide investment advice or recommendations, he appreciates your feedback;

click here

to send him an email.